Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$20.18 - $33.33 $889,413 - $1.47 Million
44,074 New
44,074 $1.09 Million
Q1 2022

May 12, 2022

SELL
$19.89 - $43.18 $184,340 - $400,192
-9,268 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$26.75 - $46.02 $247,919 - $426,513
9,268 New
9,268 $405,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Gyon Technologies Capital Management, LP Portfolio

Follow Gyon Technologies Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.